---
title: "SSY Group wins China NMPA approval for choline fenofibrate sustained-release capsules"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292848979.md"
description: "SSY Group has obtained China NMPA approval for the production and registration of choline fenofibrate sustained-release capsules (135 mg). This Type 4 chemical drug approval is recognized as passing China's generic consistency evaluation, facilitating its commercialization in the lipid-lowering market."
datetime: "2026-07-16T04:09:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292848979.md)
  - [en](https://longbridge.com/en/news/292848979.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292848979.md)
generator: "portal-rs"
---

# SSY Group wins China NMPA approval for choline fenofibrate sustained-release capsules

-   SSY Group won China NMPA production and registration clearance for choline fenofibrate sustained-release capsules (135 mg), a type 4 chemical drug. \* The approval is treated as passing China’s generic consistency evaluation, supporting commercialization in the lipid-lowering market. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260716-12246293), on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [02005.HK](https://longbridge.com/en/quote/02005.HK.md)
- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [Huatai Securities Sticks to Their Buy Rating for SSY Group (LJUIF)](https://longbridge.com/en/news/297389381.md)
- [SSY Group says China NMPA clears generic consistency review for diltiazem tablets 30 mg](https://longbridge.com/en/news/297758026.md)
- [SSY Group H1 FY26 net profit attributable to shareholders rises 13% to HK$320.32 million; revenue climbs 9.9% to HK$2.36 billion](https://longbridge.com/en/news/297041744.md)
- [SSY Group wins China NMPA approval for ozagrel sodium injection](https://longbridge.com/en/news/296882931.md)
- [SSY Group Delivers Profit Growth and Higher Dividend Amid Sector Reforms](https://longbridge.com/en/news/297005091.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**